跳转至内容
Merck
CN

SML2035

Didox

≥98% (HPLC)

别名:

3,4-Dihydroxybenzohydroxamic acid, 3,4-Dihydroxyphenylhydroxamic acid, BRN 2096682, CCRIS 7909, N,3,4-Trihydroxybenzamide, NSC 324360, NSC-324360, VF 147

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C7H7NO4
化学文摘社编号:
分子量:
169.13
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI

1S/C7H7NO4/c9-5-2-1-4(3-6(5)10)7(11)8-12/h1-3,9-10,12H,(H,8,11)

SMILES string

OC1=CC=C(C(NO)=O)C=C1O

InChI key

QJMCKEPOKRERLN-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

color

white to light brown

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

Biochem/physiol Actions

Didox is a ribonucleotide reductase (RNR) inhibitor that inhibits proliferation of and decreased secretion of cytokines IL-6, IFN-g, TNF-a, IL-2, IL-13, IL-10 and IL-4. Didox inhibits proliferation of tamoxifen-resistant breast cancer cells. Didox is an antioxidant that potentiates the cytotoxic profile of doxorubicin.
ribonucleotide reductase (RNR) inhibitor; antioxidant.

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Ahmed M Al-Abd et al.
European journal of pharmacology, 718(1-3), 361-369 (2013-09-12)
The use of adjuvant therapies in cancer treatment is rationalized by potentiating the efficacy and/or protecting from the major side effects of chemotherapeutics. Didox, besides its antioxidant properties, is an inhibitor for DNA synthesis and repair which might recommend its
Khyati N Shah et al.
Molecular cancer research : MCR, 12(3), 394-407 (2013-12-24)
Acquired tamoxifen resistance develops in the majority of hormone-responsive breast cancers and frequently involves overexpression of the PI3K/AKT axis. Here, breast cancer cells with elevated endogenous AKT or overexpression of activated AKT exhibited tamoxifen-stimulated cell proliferation and enhanced cell motility.
Sahar A Khaleel et al.
Scientific reports, 6, 36855-36855 (2016-11-15)
Doxorubicin (DOX) has limited efficacy in colorectal cancer due to multi-drug resistance. Resveratrol (RES) and didox (DID) are polyhydroxyphenols with potential chemosensitizing effects. Herein, we assessed the chemomodulatory effects of RES and DID to DOX in colorectal cancer cells. Equitoxic

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持